BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Diatherix Laboratories Receives FDA Emergency Use Authorization for the Detection of the Influenza A H1N1-09 Pandemic Flu


10/13/2009 10:55:41 AM

HUNTSVILLE, Ala., Oct. 13 /PRNewswire/ -- DIATHERIX Laboratories, Inc. is pleased to announce it has been granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its DIATHERIX H1N1-09 Influenza Test. The test utilizes the company's proprietary molecular technology, known as Target Enriched Multiplex Polymerase Chain Reaction (Tem-PCR), which is used for the detection of the H1N1-09 influenza viral RNA.

The DIATHERIX H1N1-09 Influenza Test allows clinicians to quickly and definitively identify H1N1-09 patients, differentiating from those who have similar symptoms. Once accurately identified, infected patients can be provided proper antiviral therapy in a timely manner. Confirmation and appropriate treatment of H1N1-09 patients can mitigate many of the negative economic and social impacts associated with a pandemic influenza outbreak. With turnaround time of 24-hours from sample receipt, clinics, hospitals, physician offices, urgent care centers and public health departments are able to treat and/or contain patients who test positive for the H1N1-09 pandemic flu virus.

DIATHERIX Laboratories provides the test within requirements set forth by the FDA for Emergency Use Authorization; the FDA has not cleared or approved this test. Under the EUA, the FDA has authorized use of DIATHERIX H1N1-09 only for the duration of the declaration of emergency. The test is intended to be used on nasopharyngeal swabs, nasal swabs, throat swabs and nasal aspirates from patients with signs and symptoms of respiratory infection in conjunction with clinical risk factors.

For information on using the DIATHERIX Tem-PCR test for the H1N1-09 virus, please visit the company's web site at www.DIATHERIX.com or call (866) 656-1179. DIATHERIX Laboratories, Inc. is located in the HudsonAlpha Institute for Biotechnology in Huntsville, Ala. DIATHERIX operates as an independent CLIA-certified clinical laboratory providing advanced multiplex molecular diagnostic services to assist healthcare providers in the detection of infectious disease. An executive office for Diatherix and headquarters for Diagnostix Network Alliance, the exclusive representative for Diatherix Laboratories, are located in Brentwood, Tenn.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Dennis Grimaud

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=86216

SOURCE DIATHERIX Laboratories, Inc.

CONTACT: Robin Embry of Lovell Communications Inc., +1-615-297-7766,
robin@lovell.com

Web site: http://www.DIATHERIX.com/



Read at BioSpace.com

   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->